Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Dietz-Fricke

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Gastroenterologie|September 11, 2025
Quality of life improves during antiviral therapy with bulevirtideJulia Carolin Eichholz, Christopher Dietz-Fricke, Simon Kristian Mrowietz, et al.
Journal of Viral Hepatitis|March 16, 2023
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNAKatja Deterding, Chengjian Xu, Kerstin Port, et al.
The Journal of Pathology|June 3, 2026
Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancerChristoph Steup, Julian Dosch, Christopher Dietz-Fricke, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|April 7, 2023
Treating hepatitis D with bulevirtide - Real-world experience from 114 patientsChristopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
Journal of Hepatology|January 10, 2025
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosisElisabetta Degasperi, Maria Paola Anolli, Mathias Jachs, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Gastroenterologie|September 11, 2025
Quality of life improves during antiviral therapy with bulevirtideJulia Carolin Eichholz, Christopher Dietz-Fricke, Simon Kristian Mrowietz, et al.
Journal of Viral Hepatitis|March 16, 2023
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNAKatja Deterding, Chengjian Xu, Kerstin Port, et al.
The Journal of Pathology|June 3, 2026
Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancerChristoph Steup, Julian Dosch, Christopher Dietz-Fricke, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|April 7, 2023
Treating hepatitis D with bulevirtide - Real-world experience from 114 patientsChristopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
Journal of Hepatology|January 10, 2025
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosisElisabetta Degasperi, Maria Paola Anolli, Mathias Jachs, et al.
Pageof 1